ZIM Laboratories Ltd
ZIMLABZIM Laboratories Ltd
ZIMLAB
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 34.84 | 2.35 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.53 | 6.56 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
ZIM Laboratories Limited is a pharmaceutical company. The Company develops, manufactures and supplies oral, solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) in various therapeutic segments.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 272.42 | 239.86 | 282.09 | 337.42 | 282.26 | 309.60 | 337.83 | 404.94 | 372.60 | 393.08 | ||||||||||
Raw Materials | 156.17 | 118.55 | 141.79 | 159.63 | 149.54 | 159.74 | 170.02 | 182.37 | 185.49 | 343.38 | ||||||||||
| Power & Fuel Cost | 6.40 | 5.35 | 5.75 | 7.19 | 7.47 | 7.04 | 9.14 | 11.09 | 13.47 | |||||||||||
| Employee Cost | 30.70 | 33.00 | 40.80 | 48.26 | 35.35 | 35.76 | 40.07 | 49.32 | 53.34 | |||||||||||
| Selling & Administrative Expenses | 28.48 | 36.64 | 42.21 | 67.10 | 40.72 | 43.06 | 53.79 | 54.02 | 49.83 | |||||||||||
| Operating & Other expenses | 22.90 | 9.98 | 7.47 | 11.16 | 22.05 | 27.08 | 19.43 | 49.73 | 23.96 | |||||||||||
EBITDA | 27.77 | 36.34 | 44.07 | 44.08 | 27.13 | 36.92 | 45.38 | 58.41 | 46.51 | 49.70 | ||||||||||
| Depreciation/Amortization | 8.76 | 9.02 | 9.79 | 11.42 | 14.41 | 15.79 | 16.03 | 17.47 | 15.95 | 17.79 | ||||||||||
| PBIT | 19.01 | 27.32 | 34.28 | 32.66 | 12.72 | 21.13 | 29.35 | 40.94 | 30.56 | 31.91 | ||||||||||
| Interest & Other Items | 13.65 | 9.82 | 9.34 | 10.59 | 12.65 | 10.90 | 8.31 | 5.58 | 6.92 | 9.73 | ||||||||||
| PBT | 5.36 | 17.50 | 24.94 | 22.07 | 0.07 | 10.23 | 21.04 | 35.36 | 23.64 | 22.18 | ||||||||||
| Taxes & Other Items | 0.26 | -1.09 | 5.82 | 6.72 | -3.22 | 2.91 | 6.49 | 10.92 | 6.39 | 6.06 | ||||||||||
| Net Income | 5.10 | 18.59 | 19.12 | 15.35 | 3.29 | 7.32 | 14.55 | 24.44 | 17.25 | 16.12 | ||||||||||
| EPS | 0.12 | 0.43 | 0.44 | 0.35 | 0.08 | 0.17 | 0.33 | 1.00 | 3.54 | 3.31 | ||||||||||
| DPS | 0.06 | 0.06 | 0.06 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.47 | 0.13 | 0.13 | 0.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| ZIM Laboratories Ltd | 32.56 | 2.35 | — |
| Sun Pharmaceutical Industries Ltd | 45.35 | 6.47 | 0.75% |
| Cipla Ltd | 28.51 | 4.38 | 0.89% |
| Torrent Pharmaceuticals Ltd | 68.45 | 16.54 | 0.84% |
Price Comparison
Compare ZIMLAB with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
ZIMLAB has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 19, 2019
Dividend/Share
₹0.50
Ex DateEx Date
Sep 19, 2019
Cash Dividend
Ex DateEx DateSep 3, 2018
Dividend/Share
₹1.00
Ex DateEx Date
Sep 3, 2018
Zim Laboratories announced that the step-down Subsidiary has been incorporated in the name of 'ZIM SCIENTIFIC OFFICE L.L.C' in Dubai, United Arab Emirates. Powered by Capital Market - Live
Net profit of Zim Laboratories declined 42.65% to Rs 2.38 crore in the quarter ended September 2024 as against Rs 4.15 crore during the previous quarter ended September 2023. Sales rose 7.35% to Rs 92.14 crore in the quarter ended September 2024 as against Rs 85.83 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales92.1485.83 7 OPM %10.3410.87 - PBDT7.969.53 -16 PBT2.965.44 -46 NP2.384.15 -43 Powered by Capital Market - Live
Zim Laboratories will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live
Zim Laboratories consolidated net profit rises 291.30% in the June 2024 quarter
Net profit of Zim Laboratories rose 291.30% to Rs 0.90 crore in the quarter ended June 2024 as against Rs 0.23 crore during the previous quarter ended June 2023. Sales rose 21.32% to Rs 81.82 crore in the quarter ended June 2024 as against Rs 67.44 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales81.8267.44 21 OPM %9.837.16 - PBDT6.184.21 47 PBT1.230.19 547 NP0.900.23 291 Powered by Capital Market - Live
Zim Laboratories will hold a meeting of the Board of Directors of the Company on 3 August 2024.Powered by Capital Market - Live
Zim Laboratories consolidated net profit rises 62.16% in the December 2022 quarter
Sintex Plastics Technology Ltd leads losers in ‘B’ group
Triveni Turbine, 2 others to trade ex-buyback today; Precision Wires India, Zim Labs to go ex-bonus
Pharma stock is 186% above 52-week-low, record date fixed for 2:1 bonus shares
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 2%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.15% to 0.1%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 2.36%, vs industry avg of 15.27%